Bictegravir is primarily used in the treatment of HIV-1 infection. It is a key component of antiretroviral therapy (ART) and is often combined with other medications to form a complete regimen. This integration inhibitor works by blocking the integrase enzyme, which is essential for the virus to replicate and integrate its genetic material into human cells. By inhibiting this process, Bictegravir helps to reduce the viral load in the body, improving immune function and slowing disease progression. It is particularly valued for its high barrier to resistance, making it a reliable option for long-term management of HIV. Additionally, Bictegravir is included in single-tablet regimens, simplifying treatment adherence for patients. Its use is recommended for both treatment-naïve individuals and those switching from other therapies, provided they do not have resistance to integrase inhibitors.